Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | BRAF | P15056 | 19/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13249634 | 0.88 | CYP3A4 (0.63) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL13249633 | 0.88 | CYP3A4 (0.63) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL25940015 | 0.87 | CYP3A4 (0.62) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL24570795 | 0.86 | CYP2C19 (0.68) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL1437671 | 0.83 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL8222877 | 0.81 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL30636771 | 0.81 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL20408825 | 0.81 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL14979878 | 0.81 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL30636731 | 0.80 | CYP2C9 (1.00) | CYP3A4CYP2C9CYP2C19BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CYP3A4 4780/4885CYP2C9 4838/4885CYP2C19 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.